• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Dapagliflozin associated with reduction in cardiovascular mortality due to lower rates of death from heart failure and sudden death – Pooled analysis of DAPA-HF and DELIVER

byZoya GomesandYuchen Dai
October 16, 2022
in Cardiology, Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this pooled analysis of 11,007 patients with heart failure in the DAPA-HF and DELIVER trials, treatment with dapagliflozin was associated with a 14% lower risk of cardiovascular death regardless of ejection fraction, due to lower rates of sudden death and HF death.

2. No difference was found between dapagliflozin vs placebo in rates of non-CV death.

Evidence Rating Level: 2 (Good)

Study Rundown: Recent clinical trials of patients with chronic heart failure (HF) across the spectrum of ejection fraction (EF) have associated sodium-glucose cotransporter 2 (SGLT-2) inhibitors with a reduction in the risk of worsening HF events or death due to cardiovascular (CV) causes. However, there is a lack of evidence examining the effects of SGLT-2 inhibitors on overall mortality and specific causes of death. Hence, the objective of this pooled secondary analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) and Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) was to examine the effects of dapagliflozin on cause-specific CV and non-CV mortality across the spectrum of EF. The intervention in the trials examined was dapagliflozin vs placebo. The main outcomes were more death in relation to baseline EF, as well as the effect of randomized treatment on cause-specific death. A total of 11,007 patients were included in the pooled data set. During follow-up, there were 1628 deaths, of which 872 were ascribed to CV deaths. Of the CV deaths, 289 were due to HF, 441 were sudden, 69 were due to stroke, 47 were due to myocardial infarction (MI), and 26 were due to other CV causes. Treatment with dapagliflozin was found to significantly reduce the risks of CV death by 14%, predominantly due to lower rates of sudden death and death from progressive HF. A strength of this study was its large sample size; however, a limitation was that due to the absence of autopsy data, the cause of death was ascertained based on clinical inference made with limited data regarding the circumstances of death, which may have impacted results.

Click to read the study in JAMA Cardiology

Relevant Reading: Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER

In-Depth [meta-analysis]: In this participant-level, pooled, prespecified secondary analysis of data from the DAPA-HF and DELIVER randomized trials, a total of 11,007 patients were included in the pooled data set (mean [SD] age, 71.7 [10.3] years; 1139 male [70.0%]). This study investigated the effects of dapagliflozin on cause-specific CV and non-CV mortality across the spectrum of EF. During follow-up, there were a total of 1628 deaths, and of those who died, 872 (53.5%) were ascribed to CV deaths, 487 (29.9%) to non-CV deaths, and 269 (16.5%) due to unknown causes. Of the CV deaths specifically, 289 (33.1%) were due to HF, 441 (50.6%) were sudden, 69 (7.9%) were due to stroke, 47 (5.4%) due to MI, 26 (3.0%) were due to other CV causes. Across the spectrum of EF in the pooled population, treatment with dapagliflozin compared with placebo was associated with lower rates of CV death (hazard ratio [HR], 0.86; 95% CI, 0.75-0.98; P = .02), and this was attributed to lower rates of sudden death (HR, 0.84; 95% CI, 0.70-1.01; P = .07) and HF death (HR, 0.88; 95% CI, 0.70-1.11; P = .30). No difference was found between dapagliflozin and placebo in rates of non-CV death (HR, 1.01; 95% CI, 0.84-1.20; P = .94).

RELATED REPORTS

Moderately accelerated cardiac pacing may be beneficial in patients with heart failure with preserved ejection fraction

Empagliflozin use is associated with slower progression of chronic kidney disease

Torsemide not associated with significant difference in all-cause mortality over 12 months compared to furosemide – The TRANSFORM-HF randomized clinical trial

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiovascular mortalitydapagliflozinheart failureHFpEF (heart failure with preserved ejection fractionSGLT-2 inhibitors
Previous Post

#VisualAbstract: Neoadjuvant atezolizumab is not effective for node-positive HER2⁺ breast cancer

Next Post

Atezolizumab does not reduce post-resection recurrence in patients with renal cell carcinoma

RelatedReports

Atrial fibrillation-specific management increases days alive and out of hospital
Cardiology

Moderately accelerated cardiac pacing may be beneficial in patients with heart failure with preserved ejection fraction

February 5, 2023
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Empagliflozin use is associated with slower progression of chronic kidney disease

January 26, 2023
Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors
Cardiology

Torsemide not associated with significant difference in all-cause mortality over 12 months compared to furosemide – The TRANSFORM-HF randomized clinical trial

January 24, 2023
Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial
Cardiology

Clinical decision-making strategy improves acute heart failure outcomes

January 12, 2023
Next Post
Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact

Atezolizumab does not reduce post-resection recurrence in patients with renal cell carcinoma

Collaborative home-based palliative care approach effective for heart failure patients

Adding sargramostim to ipilimumab may improve survival in advanced melanoma

Nivolumab plus ipilimumab improves recurrence-free survival in patients with resected advanced melanoma

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Low-dose pirfenidone may be noninferior to standard dosing in patients with idiopathic pulmonary fibrosis
  • Protein-truncating variants in apolipoprotein B and PCSK9 genes associated with lower exposure to atherogenic LDL cholesterol and risk of coronary heart disease
  • College campus monkeypox outbreaks can be controlled with timely detection and isolation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options